<DOC>
	<DOCNO>NCT01187459</DOCNO>
	<brief_summary>Background : Crohn 's disease ( CD ) , type Inflammatory Bowel Disease ( IBD ) , chronic relapse inflammatory disorder digestive system . CD affect ~112,000 individual Canada , 20-25 % diagnose childhood adolescence . The specific cause CD remain unknown ; however , hypothesized CD involve complex interaction several factor , include genetically susceptible host , intestinal mucosal immune system microbe population . Several dietary factor explore potential role etiology CD . However , consensus role diet emerge . Recent evidence suggest plausible link lack Vitamin D CD . Purpose &amp; Hypothesis : The investigator primary hypothesis great proportion pediatric CD patient achieve optimal 25OHD concentration ( &gt; 75 nmol/L ) 2000 IU/d 400 IU/d Vitamin D. Methods : Pediatric Crohn 's Disease patient 8-18 year age , remission least 4 week indicate Pediatric Crohn 's Disease Activity Index ( PCDAI ) &lt; 10 recruited double-blind , randomize , control trial receive one two dosage vitamin D ( 10 50 ug/day ) ask continue supplementation 6 month . Vitamin D level measure blood baseline , 3 month , 6 month . Dietary vitamin D intake estimate use food frequency lifestyle questionnaire . Data analyze use multiple regression analysis control baseline value . Expected Results Conclusions : It expect great proportion child receive 50 ug/day vitamin D supplement achieve blood vitamin level &gt; 75 nmol/L compare child receive 10 ug/day . This data aid policy maker , parents/children healthcare worker recommend appropriate vitamin D dosage pediatric crohn 's population .</brief_summary>
	<brief_title>Vitamin D Pediatric Crohn 's Disease</brief_title>
	<detailed_description>Trial Objectives : Our primary hypothesis great proportion pediatric CD patient achieve optimal 25OHD concentration ( &gt; 75 nmol/L ) 2000 IU/d 400 IU/d Vitamin D. Our primary objective determine whether proportion pediatric CD patient achieve 25OHD concentration &gt; 75 nmol/L great receive 2000 IU/d 400 IU/d Vitamin D. Our secondary objective determine patient receive 2000 IU Vitamin D likely remain remission [ Pediatric Crohn 's Disease Activity Index ( PCDAI ) &lt; 20 ] receive 400 IU/d . Study Design : This parallel study design two level Vitamin D : 400 IU/d , 2000 IU/d supplement Vitamin D3 . Study Duration : 6 Months Number Sites ( inside outside Canada ) : 1 . Children 's Women 's Hospital British Columbia 2 . McMaster 's Children 's Hospital List Investigators : - Tim Green , PhD . Faculty Land Food Systems , UBC - Kevan Jacobson MD . Pediatric GI , UBC - Robert Issenman MD . Pediatric GI , McMaster University - Susan Barr PhD . Faculty Land Food Systems , UBC Sample Size : Forty-five subject per group allow u detect little 20 % difference proportion participant achieve 25OHD &gt; 75 nmol/L two dos 80 % power one side 0.05 . Assuming 10 % attrition rate need recruit 50 subject per group . Clinical experience indicate approximately 50 % pediatric CD patient relapse 6 month base elevate PCDAI ( &gt; 20 ) . Forty-five subject per group allow u detect 50 % difference CD relapse two dose 80 % power one side 0.05 . Patient Population : Pediatric CD patient patient pediatric gastroenterology service BC McMaster Children 's Hospitals . Inclusion Criteria : Patients eligible participate diagnosis CD , 8-18 year age , remission least 4 week indicate PCDAI &lt; 10 . Exclusion Criteria : Patients ineligible active disease PCDAI &gt; 10 , take corticosteroid , take 400 IU Vitamin D enrollment . NHP Formulation : Vitamin D dose 10 50 ug ( 400 , 2000 IU ) 400 IU DIN # 02231624 2000 IU Dosage Regimen : Patients randomly assign one two supplemental dos vitamin D3 ( 10 , 50 ug/d ) Prestudy Screening Baseline Evaluation : Patients parent/guardian meet inclusion criterion consent enrol assign without bias dose group . A one-hour fasting blood sample spot urine collection collect , PCDAI administer , patient complete food frequency questionnaire ( FFQ ) include information Vitamin D calcium supplement use ( include dose duration ) well lifestyle demographic questionnaire . Treatment Visit : One-hour fasting blood spot urine collect PCDAI administer baseline , 3 month ( +/- 1 week ) , 6 month ( +/- 1 week ) baseline . 25OHD concentration think stabilize 8 week supplementation constant dose . Premature Withdrawal/Discontinuation Criteria : Discontinuation criterion individual subject include violation exclusion criterion , severe non-compliance protocol , occurrence adverse event judge severe enough discontinuation . Subjects also free voluntarily discontinue study time . Rescue Medication : Regular dosage 400 IU vitamin D Washout Period : None Dietary Assessment : Calcium Vitamin D intake food previous month estimate use food frequency questionnaire validate use variety ethnic group ( From S Whiting ; U Sask ) . Pediatric Crohn 's Disease Activity Index : The PCDAI use assess severity disease . It consist patient recall , laboratory value , clinical examination . Scores 10 indicate remission score 20 indicate active disease ( attach ) . Laboratory Assessment : Erythrocyte Sedimentation Rate , serum calcium , serum albumin , serum creatinine , urinary calcium urinary creatinine measure hospital pathology lab use standard procedure . Serum 25OHD , PTH measure use automate chemiluminescent assay system ( Liaison , Diasorin ) BC Biolabs . Efficacy Analysis : The proportion patient achieve 25OHD 75 nmol/L dosage 6 month compare use Chi-squared test . Likewise proportion participant remain remission ( PCDAI &lt; 20 ) also compare use Chi-squared test . Data initially analyze intent-to-treat outcome . In case dropout miss data last observation carried-forward . A second analysis carry outcome use subject complete data 80 % compliant supplement use ( as-treated analysis ) . Differences characteristic participant group baseline determine use Student 's t-test continuous chi-square test Fisher 's Exact Test categorical variable . Safety Analysis : Adverse event record accord Good Clinical Practice Guidelines guideline university 's human research ethic board . Adverse event occurrence compare descriptively treatment placebo group . Safety also assess part blood collection ( Serum Ca Serum PTH Serum P ) . Statistical Analysis : Data initially analyze intent-to-treat outcome . In case dropout miss data last observation carried-forward . A second analysis carry outcome use subject complete data 80 % complaint supplement use ( as-treated analysis ) . Differences characteristic participant group baseline determine use Student 's t-test continuous chi-square test Fisher 's Exact Test categorical variable . The primary endpoint dosages 3 month evaluate use Chi-squared test . Dose response ( ug Vitamin D3 per nmol/L increase 25OHD ) child determine use multiple regression analysis 25OHD dependent variable , vitamin D dose enter continuous variable , baseline vitamin D covariate .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients eligible participate diagnosis CD , 818 year age , remission least 4 week indicate PCDAI &lt; 10 . Patients ineligible active disease PCDAI &gt; 10 , take corticosteroid , take 400 IU Vitamin D enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Dose Response</keyword>
</DOC>